Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 11/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17176168 | 1.00 | PIK3R1 (0.38) | PIK3R1PIK3CASPRDPP4DPP7 | |
| SCHEMBL17176110 | 0.84 | SPR (0.37) | PIK3R1PIK3CASPRDPP4DPP7 | |
| SCHEMBL17176147 | 0.84 | SPR (0.37) | PIK3R1PIK3CASPRDPP4DPP7 | |
| SCHEMBL17173001 | 0.84 | PIK3R1 (0.34) | PIK3R1PIK3CADPP4DPP7CCR1 | |
| SCHEMBL17172999 | 0.84 | PIK3R1 (0.34) | PIK3R1PIK3CADPP4DPP7CCR1 | |
| SCHEMBL17177185 | 0.82 | CHRNB2 (0.39) | PIK3R1PIK3CASPRDPP4DPP7 | |
| SCHEMBL17176073 | 0.79 | DPP4 (0.42) | PIK3R1PIK3CADPP4DPP7 | |
| SCHEMBL17176096 | 0.79 | DPP4 (0.42) | PIK3R1PIK3CADPP4DPP7 | |
| SCHEMBL18390373 | 0.79 | USP2 (0.40) | PIK3R1PIK3CACYP3A4RETTSHR | |
| SCHEMBL17177220 | 0.78 | DPP4 (0.41) | PIK3R1PIK3CASPRDPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260439-B2 | Dihydropyrrolopyrimidine derivatives | PFIZER INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150291604-A1 | DIHYDROPYRROLOPYRIMIDINE DERIVATIVES | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2015155624-A1 | DIHYDROPYRROLOPYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291604-A1 | DIHYDROPYRROLOPYRIMIDINE DERIVATIVES | DPYD, TPD52L2, DTYMK | PIK3R1 2181/4885PIK3CA 1837/4885SPR 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.